Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
about
Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disordersClinical significance of preoperative liver stiffness measurements in primary HBV-positive hepatocellular carcinoma.
P2860
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
@en
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
@nl
type
label
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
@en
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
@nl
prefLabel
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
@en
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Liver stiffness measurement for risk assessment of hepatocellular carcinoma.
@en
P2093
Akihisa Tatsumi
Fumitake Amemiya
Mika Miura
Minoru Sakamoto
Mitsuaki Sato
Nobutoshi Komatsu
Nobuyuki Enomoto
Shinya Maekawa
Taisuke Inoue
Yasuhiro Nakayama
P2860
P304
P356
10.1111/HEPR.12377
P577
2014-10-20T00:00:00Z